Addressing Ethical Issues in Continuous Monitoring Using Wearables in Trials

Introduction: Ethics at the Heart of Digital Monitoring

While wearables offer transformative potential in clinical trials—enabling continuous monitoring and rich data capture—they also raise significant ethical concerns. The move from episodic site visits to 24/7 biometric surveillance demands a recalibration of ethical norms in clinical research.

Regulatory frameworks such as FDA guidance on digital health technologies and ICH E6(R3) emphasize the importance of safeguarding participant rights and dignity when deploying continuous monitoring tools. Sponsors and CROs must balance scientific benefit with respect for autonomy, privacy, and informed decision-making.

In a decentralized diabetes study, continuous glucose monitors led to participant withdrawal after subjects felt “watched all the time”—underscoring the psychological impact of persistent monitoring.

Informed Consent in the Era of Digital Surveillance

Traditional informed consent must evolve when wearables are used for continuous data collection. Ethics committees expect:

• Clear disclosure of what is collected, when, and why
• Transparency about data access (e.g., sponsor, CRO, wearable vendor)
• Explanation of whether participants can pause or disable monitoring
• Explicit consent for secondary use of data, if applicable

Consider the following dummy table outlining key consent clauses and ethical justifications:

Privacy, Data Minimization, and Governance

Continuous monitoring generates high-resolution biometric data. Without strict controls, this can infringe on privacy and lead to overcollection. Sponsors must:

• Define minimal data needed for endpoints (e.g., daily average HR vs raw second-level stream)
• Implement role-based access and audit logs
• Encrypt data both in transit and at rest
• Limit storage duration per country-specific data protection laws

In a wearable-driven sleep study, unnecessary GPS tracking was flagged by the IRB and removed—highlighting the need for feature-specific justification.

Ethics reviews now demand detailed data governance sections in protocols and informed consent forms, especially in multi-jurisdictional studies.

Participant Burden and Psychological Impact

Beyond privacy, wearables can affect mental well-being:

• Feelings of surveillance or judgment from monitoring
• Obligation to “perform health” or adjust behavior due to observation
• Device fatigue from wearing sensors daily
• Fear from automated alerts (e.g., false alarms)

Sponsors should consider administering patient-reported outcome (PRO) tools measuring perceived burden, anxiety, or tech fatigue. Protocols should allow participants to opt-out or switch devices without penalty.

According to PharmaGMP.in, trials with wearable “pause buttons” had 32% fewer withdrawals due to tech-related stress.

Respecting Autonomy Through Flexibility and Control

Empowering participants to make choices during the study fosters ethical engagement. Key autonomy-enhancing features include:

• Pause Options: Letting participants turn off sensors for private moments
• Data Visibility: Giving patients access to their own health metrics
• Dynamic Consent: Allowing participants to modify their data-sharing preferences mid-study
• Device Alternatives: Offering low-tech options if wearables are burdensome

In a CRO-led mental health study, enabling participants to temporarily disable biometric tracking during therapy sessions improved enrollment by 17% and reduced early dropout.

Ethical Oversight and IRB/Sponsor Responsibilities

IRBs and sponsors share responsibility for ethical wearable implementation. IRBs should review:

• Scope and intrusiveness of monitoring
• Potential psychosocial risks from alerts or continuous feedback
• Risk mitigation strategies (e.g., device training, opt-outs)
• Alignment with the principle of proportionality—benefit vs burden

Sponsors, in turn, must submit detailed device justification, provide participant debriefing plans, and allow ethics amendments based on participant feedback.

For example, one IRB required an SOP for handling wearable-triggered panic in subjects, after reviewing a PTSD trial with heart rate-triggered alerts.

Best Practices for Ethical Wearable Deployment

Based on current literature, regulator statements, and trial experience, sponsors can adopt these best practices:

• Limit data collection to what is necessary for the protocol-defined endpoints
• Make informed consent interactive—include visuals and FAQs
• Regularly assess device wearability and burden
• Implement feedback loops for participants to express concerns
• Ensure complete transparency on data use, storage, access, and sharing
• Review real-time monitoring through a bioethics lens—not just tech feasibility

Sponsors that treat wearables not only as tools—but as touchpoints of trust—will gain long-term credibility with regulators, participants, and ethics boards.

Conclusion: Centering Ethics in Digital Trials

As wearables become standard in clinical trials, ethical concerns will grow in complexity and urgency. Autonomy, privacy, dignity, and transparency must be foundational pillars in every phase—from protocol design to device selection and participant communication.

By proactively addressing the ethical dimensions of continuous monitoring, sponsors and CROs can build not just compliant trials, but participant-centered research ecosystems. In the digital age, data integrity begins with ethical integrity.